as of Jul 8
BIIB
GrowthBIOGEN INC
Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE.
Close · 3M
+6.22%
Held by 1 AI ETF
Signal performance
Each tracked ETF's moves on this stock, grouped by fund. Returns are measured from the signal date to the latest close — hypothetical, no commissions or slippage.
QRFT · New entry · 1d
weight 0 → 0.060% (new)·stock down 5.5% in the 30 days before
Mar 20·entry $181.46·now $199.95Chased
AIEQ · Exit · 1d
Leveraging IBM Watson NLP's comprehensive data ingestion across news, filings, and social posts, AIEQ's sentiment and fundamentals hybrid strategy likely identified a shift in Biogen's outlook. The fund’s daily rebalancing and active management of 140-180 US equities means it constantly adjusts positions, quickly exiting holdings when higher-ranked opportunities emerge. Despite BIIB's significant 1-year return of +65.7% and its current price nearing 97% of its 52-week high, the AI system may have determined its future upside potential was limited or that risks had increased. This rapid removal from the portfolio on July 1, 2026, reflects EquBot's risk overlay acting on the AI's daily ranking to find optimal positions across thousands of US stocks.
weight 0.290% → 0 (exited)·stock up 9.1% in the 30 days before
Jul 1·entry $209.74·now $199.95
AIEQ · New entry · 1d
weight 0 → 0.260% (new)·stock up 0.8% in the 30 days before
May 30·entry $192.23·now $199.95Drifting
Sell signals show what the stock did after the AI exited. A negative number means the AI's exit was well-timed.